Telix Reports Third Quarter 2026 Financial Performance
Telix reported Q3 2026 group revenue of US$245 million, up 19% year-over-year, with Precision Medicine revenue up 30% to US$201 million on strong Gozellix and Illuccix demand. The company reaffirmed FY26 revenue and other income above US$1 billion, tracking to the upper end of its US$950-970M revenue guidance, and narrowed R&D guidance to US$240-260M. Key strategic developments include the transformative US$1.65 billion merger with ITM (plus up to US$700M contingent), FDA approval of Pixclara for glioma imaging with first commercial doses already administered, and completion of Phase 3 BiPASS enrollment with FDA Fast Track Designation.
Key figures
- Revenue
- 245000000
- Guidance
- FY26 revenue and other income in excess of US$1 billion; revenue tracking to upper end of US$950M-US$970M guidance plus US$40M other income; R&D expenditure revised to US$240M-US$260M
- Revenue Yoy
- 19%
- Tms revenue
- 44000000
- Tms revenue yoy
- (6)%
- Group revenue qoq
- (1)%
- Precision medicine revenue
- 201000000
- Precision medicine revenue yoy
- 30%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.